

IGI LABORATORIES, INC  
Form 8-K  
October 09, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 3, 2014

**IGI LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**001-08568**  
**(Commission File Number)**

**01-0355758**  
**(IRS Employer Identification No.)**

**105 Lincoln Avenue**  
**Buena, New Jersey**  
**(Address of principal executive offices)**

**08310**  
**(Zip Code)**

Registrant's telephone number, including area code: **(856) 697-1441**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02.**

**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d)

On October 3, 2014, the Board of Directors (the **Board**) of IGI Laboratories, Inc. (the **Company**) approved the appointment of Steven Koehler to serve as a member of the Board effective October 13, 2014. Mr. Koehler has also been appointed to serve as the Chairman of the Company's audit committee of the Board, and the Board has determined that Mr. Koehler is an audit committee financial expert as defined in Item 407(d)(5) of Regulation S-K.

There are no arrangements or understandings between Mr. Koehler and any other person pursuant to which Mr. Koehler was appointed as a director. There are no transactions to which the Company is a party and in which Mr. Koehler has a material interest that is required to be disclosed under Item 404(a) of Regulation S-K.

Mr. Koehler will be compensated for his service on the Board in accordance with the Company's director compensation policy and will be reimbursed for reasonable expenses incurred in connection with his service on the Board. In addition, the Company will enter into its standard form of director and officer indemnification agreement with Mr. Koehler.

**Item 8.01**

**Other Events.**

The Company issued a press release in connection with the appointment of Mr. Koehler to the Board. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01**

**Financial Statements and Exhibits.**

(d)

Exhibits

**Exhibit Number**

99.1

**Description**

Press Release of IGI Laboratories, Inc. dated October 9, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI LABORATORIES, INC.**

Date: October 9, 2014

By: /s/ Jenniffer Collins

Name:

Jenniffer Collins

Title:

Chief Financial Officer